1. CLIA-waived Status Available to Certified Providers for COVID-19 Codes
Effective retroactively for dates of service on or after October 6, 2020, in accordance with the recently published Medicare Learning Network (MLN) Matters MM12318 from the Centers for Medicare & Medicaid Services (CMS), claims for CPT® code 87637 and PLA codes 0240U and 0241U may be billed with modifier QW to indicate the provider is performing the procedure using a Clinical Laboratory Improvement Amendments (CLIA)-waived test kit. Providers should ensure they have a valid, current CLIA certificate before submitting claims for these codes with the QW modifier.
Codes affected are listed below:
||Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
||Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected
||Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected
An Erroneous Payment Correction (EPC) will be implemented to reprocess denied claims with dates of service on or after the effective date of this billing policy, that were appropriately submitted based on the guidance published in this article, but erroneously denied because Medi-Cal had not yet implemented the system changes to support appropriate adjudication. Providers may also elect to use this updated billing policy to correct and resubmit previously denied claims as described in the CIF Submission and Timeliness Instructions section of the Provider Manual.
|Clinics and Hospitals
Chronic Dialysis Clinics
|path bil (16, 17)
2. Correction: Pathology Benefit Article with Incorrect Effective Date Removed
The article New Pathology Benefits for Gene Analysis posted briefly on the Medi-Cal website on August 16, 2021. It was discovered the effective date in the article was inaccurate. The article was removed from the website and will publish at a later, more appropriate time with the correct effective date for the following services.
||TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)
||TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)
||TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
We are sorry for any inconvenience this has caused.
3. Get the Latest Medi-Cal News: Subscribe to MCSS Today
The Medi-Cal Subscription Service (MCSS) is a free service that keeps you up-to-date on the latest Medi-Cal news. Subscribers receive subject-specific emails shortly after urgent announcements and other updates post on the Medi-Cal website.
Subscribing is simple and free!
- Go to the MCSS Subscriber Form
- Enter your email address and ZIP code and select a subscriber type
- Customize your subscription by selecting subject areas for NewsFlash announcements, Medi-Cal Update bulletins and/or System Status Alerts
After submitting the form, a welcome email will be sent to the provided email address. If you are unable to locate the welcome email in your inbox, check your junk email folder.
For more information about MCSS, please visit the MCSS Help page.
4. Provider Manual Revisions
Pages updated due to ongoing provider manual revisions:
Download PDF (Portable Document Format) reader from the Web Tool Box